ABCL
Price
$12.28
Change
+$0.10 (+0.82%)
Updated
Nov 4 closing price
Capitalization
3.98B
4 days until earnings call
Intraday BUY SELL Signals
PRME
Price
$4.97
Change
+$0.42 (+9.23%)
Updated
Nov 4 closing price
Capitalization
901.44M
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs PRME

ABCL vs PRME Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABCL vs. PRME commentary
Nov 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and PRME is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABCL with price predictions
Nov 04, 2026

ABCL's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for ABCL moved out of overbought territory on October 01, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 instances where the indicator moved out of the overbought zone. In 27 of the 30 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ABCL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 32 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.

ABCL moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ABCL crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

ABCL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ABCL entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on ABCL as a result. In 75 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

Following a +10.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in 207 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.441) is normal, around the industry mean (2.904). P/E Ratio (-22.741) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for PRME with price predictions
Nov 04, 2026

PRME's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for PRME moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 instances where the indicator moved out of the overbought zone. In 17 of the 17 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 40 cases where PRME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

PRME broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PRME as a result. In 57 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for PRME just turned positive on October 06, 2026. Looking at past instances where PRME's MACD turned positive, the stock continued to rise in 30 of 35 cases over the following month. The odds of a continued upward trend are 86%.

PRME moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PRME crossed bullishly above the 50-day moving average on October 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.

Following a +11.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in 159 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 98 of 114 cases where PRME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.451) is normal, around the industry mean (2.904). P/E Ratio (-4.733) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PRME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ABCL vs PRME: Fundamental Ratings
ABCL
PRME
OUTLOOK RATING
1..100
1630
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9495
PRICE GROWTH RATING
1..100
3435
P/E GROWTH RATING
1..100
9894
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABCL's Valuation (10) in the null industry is in the same range as PRME (27). This means that ABCL’s stock grew similarly to PRME’s over the last 12 months.

ABCL's Profit vs Risk Rating (100) in the null industry is in the same range as PRME (100). This means that ABCL’s stock grew similarly to PRME’s over the last 12 months.

ABCL's SMR Rating (94) in the null industry is in the same range as PRME (95). This means that ABCL’s stock grew similarly to PRME’s over the last 12 months.

ABCL's Price Growth Rating (34) in the null industry is in the same range as PRME (35). This means that ABCL’s stock grew similarly to PRME’s over the last 12 months.

PRME's P/E Growth Rating (94) in the null industry is in the same range as ABCL (98). This means that PRME’s stock grew similarly to ABCL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABCLPRME
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
COMPARISON
Comparison
Nov 05, 2026
Stock price -- (ABCL: $12.28 vs. PRME: $4.97)
Brand notoriety: ABCL and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 61% vs. PRME: 80%
Market capitalization -- ABCL: $3.98B vs. PRME: $901.44M
ABCL [@Biotechnology] is valued at $3.98B. PRME’s [@Biotechnology] market capitalization is $901.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $139.16B. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 1 FA rating(s) are green while PRME’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABCL and PRME are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 3 TA indicator(s) are bullish while PRME’s TA Score has 6 bullish TA indicator(s).

  • ABCL’s TA Score: 3 bullish, 7 bearish.
  • PRME’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PRME is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а -9.97% price change this week, while PRME (@Biotechnology) price change was -7.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -11.00%, and the average quarterly price growth was -16.20%.

Reported Earning Dates

ABCL is expected to report earnings on Nov 09, 2026.

PRME is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Biotechnology (-3.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+0.82%
RXRX - ABCL
57%
Loosely correlated
+5.43%
ABSI - ABCL
57%
Loosely correlated
+4.80%
CRSP - ABCL
57%
Loosely correlated
+3.57%
VCYT - ABCL
56%
Loosely correlated
+4.43%
NTLA - ABCL
53%
Loosely correlated
+3.79%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+9.23%
CRSP - PRME
66%
Loosely correlated
+3.57%
BEAM - PRME
64%
Loosely correlated
+5.55%
RXRX - PRME
62%
Loosely correlated
+5.43%
EDIT - PRME
62%
Loosely correlated
+4.62%
RCKT - PRME
55%
Loosely correlated
+3.98%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MKL1954.5156.13
+2.96%
Markel Group
BLSH23.130.17
+0.74%
Bullish
NMTC0.95-0.03
-3.06%
NeuroOne Medical Technologies Corporation
ACDC3.97-0.20
-4.80%
ProFrac Holding Corp
CHOW2.99-1.09
-26.72%
ChowChow Cloud International Holdings Ltd